Mineralys Therapeutics Quote - MLYS

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

12.28

Bid

12.00

Offer

12.35

Volume

123

0.00 Day's Range 0.00

5.85 52 Week Range 16.905

Market Cap

610.644M

Previous Close

12.28

Open

Last Trade

12.162

Last Trade Time

23:38:12

Financial Volume

VWAP

Average Volume (3m)

182,077

Shares Outstanding

49,726,675

Dividend Yield

PE Ratio

-8.49

Earnings Per Share (EPS)

-1.45

Revenue

Net Profit

-71.9M

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.mineralystx.com

Headquarters

Wilmington, Delaware, USA

Founded

Mineralys Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MLYS. The last closing price for Mineralys Therapeutics was US$12.28. Over the last year, Mineralys Therapeutics shares have traded in a share price range of US$ 5.85 to US$ 16.905.

Mineralys Therapeutics currently has 49,726,675 shares in issue. The market capitalisation of Mineralys Therapeutics is US$610.64 million. Mineralys Therapeutics has a price to earnings ratio (PE ratio) of -8.49.

Form 8-K - Current report

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to...

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.56	4.77815699659	11.72	12.34	11.48	95403	12.04406046	CS
4	0.42	3.5413153457	11.86	12.445	11.1	112964	11.82204634	CS
12	-0.96	-7.25075528701	13.24	15.12	8.58	182077	12.14021283	CS
26	-0.3	-2.38473767886	12.58	15.12	8.58	179641	12.31584902	CS
52	2.78	29.2631578947	9.5	16.905	5.85	176029	11.34779229	CS
156	-8.82	-41.8009478673	21.1	21.98	5.85	186613	12.83398825	CS
260	-8.82	-41.8009478673	21.1	21.98	5.85	186613	12.83398825	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
APIAgora Inc	US$ 5.6888 (106.87%)	34.55M
KXINKaixin Holdings	US$ 0.24585 (95.12%)	90.75M
ICCTiCoreConnect Inc	US$ 0.5755 (64.43%)	48.64M
MTCMMTec Inc	US$ 0.6395 (36.50%)	28.18M
LXLexinFintech Holdings Ltd	US$ 4.58 (32.75%)	5.97M
EGRXEagle Pharmaceuticals Inc	US$ 2.4384 (-31.51%)	308.49k
AREBAmerican Rebel Holdings Inc	US$ 5.24 (-30.30%)	159.81k
ZENAZenaTech Inc	US$ 6.1565 (-30.04%)	36.42k
HUBCWHub Cyber Security Ltd	US$ 0.01 (-27.01%)	10.42k
WINTWindtree Therapeutics Inc	US$ 1.722 (-16.81%)	225.32k
KXINKaixin Holdings	US$ 0.126 (0.00%)	74.58M
ICCTiCoreConnect Inc	US$ 0.6609 (88.83%)	31.97M
APIAgora Inc	US$ 6.02 (118.91%)	29.61M
MTCMMTec Inc	US$ 0.4685 (0.00%)	25.49M
DUOFangDD Network Group Ltd	US$ 4.26 (25.66%)	18.18M